Lab Manager | Run Your Lab Like a Business

Industry News

STACS DNA to Expand Healthcare and Forensics Sample Tracking with Investment from InVita Healthcare Technologies

STACS DNA to Expand Healthcare and Forensics Sample Tracking with Investment from InVita Healthcare Technologies

Tracking samples improves patient safety and productivity while reducing risk for hospitals and labs

STACS DNA

OTTAWA, ON, CANADA — May 18, 2021 — STACS DNA, the world leader in sexual assault kit tracking and software provider to the largest forensic DNA labs in North America, announced today it is receiving investment from InVita Healthcare Technologies. InVita is a leading software provider for complex medical environments including blood, plasma, tissue, and implants. This investment will expedite the growth of STACS DNA’s sample tracking software in the health care and forensics markets.

“We welcome STACS DNA and its world-class suite to our portfolio of solutions for complex medical environments,” said Todd Collins, President and CEO of InVita. “Incorporating health care and forensic DNA sample tracking into InVita’s offerings supports our mission to deliver the most innovative and comprehensive solutions for managing complex medical workflows to our customers. We are proud to be working with the leader in this space.”

STACS DNA remains committed to serving the forensic market, as it has for more than 20 years. In parallel, it can now expand into healthcare with Track-Kit™ for tracking sexual assault kits and newborn screening specimens, and STACS™ laboratory information management systems. These solutions are trusted by thousands of users at hospitals, laboratories, government agencies, and other stakeholders to track samples, manage inventory, improve information-sharing, and increase transparency.

“We are excited to become part of InVita,” said Jocelyn Tremblay, president and chief operating officer, STACS DNA. “Through our collaboration, we can leverage our forensics-grade sample tracking solutions inside the lab and out to improve patient safety, increase productivity, and reduce risk related to medical laboratory testing. Our combined resources will build on our success and take our products to the next level.